Monthly Archives: June 2020

Daniel Yomtobian – On the Advantages of New Ad Formats

For a time, brands were able to get eyeballs by relying primarily on content, video, and influencer marketing

Los Angeles, CA – June 30, 2020 /MarketersMedia/

Businesses that want to be successful in the digital era must be ready to implement groundbreaking techniques. Revolutionary ideas make all the difference in the marketing sector, where the target population loses interest fast due to the high amount of available content. “In this excessively saturated market, even the most creative agency can find it a massive challenge to break through all the clutter,” notes Daniel Yomtobian, a prominent entrepreneur and business leader in the online media space. “The ubiquity of ads has led to banner blindness and consumer fatigue, eroding engagement levels and undermining the success of brand campaigns. To their credit, marketers are rising to the challenge and embracing innovative ad formats that often exceed expectations in terms of the benefits they deliver.”

For a time, brands were able to get eyeballs by relying primarily on content, video, and influencer marketing, but as consumer behaviors kept changing and new platforms gained popularity, they were forced to consider formats that would minimize intrusion while promoting engagement, Daniel Yomtobian comments. The profound shift to mobile devices and the disruptive force that are video streaming services have created tremendous opportunities for innovation and hugely improved advertisers’ chances of boosting their returns on investment (ROI). Interactive ads have emerged as one of the most effective new formats, allowing brands not only to grab and retain consumers’ attention but also improve conversion rates and brand recall. By giving viewers the ability to interact with an ad, marketers are enhancing the user experience, which is an important factor in building brand loyalty. Also known as immersive or engagement ads, these creative offerings take the game to a whole new level through the incorporation of 360-degree video, augmented reality (AR), and virtual reality (VR) for a richer, more impactful, and more personalized experience, Daniel Yomtobian adds.

Just as mobile devices are becoming the platform of choice for content consumption, so streaming services are disrupting the traditional TV landscape and forcing digital-centric companies to re-evaluate their advertising practices. Part of the challenge lies in preserving the ad revenue stream while catering to consumers who have often cut the cord to escape the barrage of intrusive, repetitive advertising, Daniel Yomtobian points out. It is, therefore, hardly surprising that some of the most innovative ideas come from streaming platforms. For example, Hulu and NBCUniversal’s Peacock are rolling out ad formats that carry great promise in terms of reducing disruption, increasing engagement, and enhancing functionality. These innovative ideas include choice-based, transactional, pause, and binge ads as well as product placement in post-production.

Starting out as a web designer, Daniel Yomtobian quickly realized that his true passion is online advertising. Considered a pioneer and innovator in this space, he has led several business ventures to success, of particular note being Advertise.com – a PPC network dedicated to helping advertisers and publishers maximize their ROI and monetize their solutions. In 2014, C-Suite Quarterly described him as a “…young leader [who] will continue to play an important role in shaping the online world of tomorrow.” Among his other accolades is the SFV Business Journal Top 40 Under 40 Award. Daniel Yomtobian holds a business marketing degree from California State University-Northridge.

Daniel Yomtobian News – Advertising Pioneer and Innovator: http://www.DanielYomtobianNews.com

Daniel Yomtobian (@DanielYomtobian) – Twitter: https://twitter.com/danielyomtobian

Daniel Yomtobian – Facebook: https://www.facebook.com/Daniel-Yomtobian-174812072662757/

Contact Info:
Name: DYI
Email: Send Email
Organization: DanielYomtobianInfo.com
Website: http://www.danielyomtobiannews.com

Video URL: https://www.youtube.com/watch?v=NoZr4UgvY8Q

Source URL: https://marketersmedia.com/daniel-yomtobian-on-the-advantages-of-new-ad-formats/88965907

Source: MarketersMedia

Release ID: 88965907

SHAREHOLDER ALERT: R WFC IDEX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / June 30, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Ryder System, Inc. (NYSE:R)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ryder-system-inc-loss-submission-form?prid=7650&wire=1
Lead Plaintiff Deadline: July 20, 2020
Class Period: July 23, 2015 – February 13, 2020

Allegations against R include that: (1) Ryder's financial results were inflated as a result of the Company's practice of overstating the residual values of the vehicles in its fleet; (2) there was no reasonable basis to believe that Ryder would sell its used vehicles for the amounts that it had assigned to them; (3) Ryder's residual values for its fleet of vehicles exceeded the expected future values that would be realized upon the sale of those vehicles; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Wells Fargo & Company (NYSE:WFC)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/wells-fargo-company-loss-submission-form?prid=7650&wire=1
Lead Plaintiff Deadline: August 3, 2020
Class Period: April 5, 2020 – May 5, 2020

Allegations against WFC include that: (i) Wells Fargo planned to, and did, improperly allocate government-backed loans under the Paycheck Protection Program ("PPP"), and/or had inadequate controls in place to prevent such misallocation; (ii) the foregoing foreseeably increased the Company's litigation risk with respect to PPP allocation, as well as increased regulatory scrutiny and/or potential enforcement actions; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ideanomics, Inc. (NASDAQ:IDEX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ideanomics-inc-loss-submission-form?prid=7650&wire=1
Lead Plaintiff Deadline: August 27, 2020
Class Period: March 20, 2020 – June 25, 2020

Allegations against IDEX include that: (i) Ideanomics' Mobile Energy Global Division in Qingdao, China (the "MEG Center") was not "a one million square foot EV expo center" as the Company had stated in press releases; (ii) the Company had been using doctored or altered photographs of the purported MEG Center in Qingdao; (iii) the Company's electric vehicle business in China was not performing nearly as strongly as Ideanomics had represented; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 595737

NanoViricides Announces Addition to Russell Microcap(R) Index

SHELTON, CT / ACCESSWIRE / June 30, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has been added to the Russell Microcap® Index effective after the U.S. markets opened yesterday, Monday, June 29, 2020.

Anil R. Diwan, PhD, President and Executive Chairman of the Company, commented, "We believe inclusion in the Russell Microcap index is a consequence of the significant progress we have made recently in advancing our novel portfolio of special purpose nanomaterials for antiviral therapy towards our first IND filing. As we approach several important milestones in the coming months, we welcome the heightened visibility that is expected to result from inclusion in this widely followed benchmark."

Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. Inclusion of NanoViricides in the Russell Microcap Index may be expected to increased participation in the NNVC stock positions of investment managers and institutional investors that purchase, follow or employ this index.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

NanoViricides is pioneering a unique platform for developing anti-viral drugs based on the "bind-encapsulate-destroy" principles. Viruses would not be able to escape a properly designed nanoviricide® drug by mutations because in doing so, it is expected that, they would lose the ability to bind their cognate cellular receptor(s) and thus fail to infect productively, becoming incompetent.

NanoViricides possesses its own cGMP-capable manufacturing capability where thousands of doses of its drugs can be manufactured rapidly. More specifically, the Company has the capability to produce multiple kilograms of the active pharmaceutical ingredient (API) per batch.

The Company is developing a therapy or drug to combat the SARS-CoV-2 virus that has caused the COVID-19 pandemic. It is anticipated that this drug that is designed to directly attack the virus, would lead to successful treatment of infected patients. It is not a drug that is designed for reducing clinical symptoms alone. The drug we are developing is not a vaccine, and does not have to be given to everyone, but will need to be given only to patients, if we can develop it successfully.

The Company has reported successful results for its broad-spectrum anti-coronavirus drug candidates in cell culture studies against multiple coronaviruses as well as in animal studies against a coronavirus called hCoV-NL63 that binds to the same human receptor as SARS-CoV-2, namely ACE2, and causes similar pathology. The Company is advancing this program towards a pre-IND application to the US FDA with the aim of progressing it further towards human clinical trials as rapidly as possible.

The Company continues to advance its first drug candidate, namely NV-HHV-101 skin cream, for the treatment of shingles rash as its first indication, towards human clinical trials. The Company is now in the process of writing and completing its IND ("Investigational New Drug") application for NV-HHV-101 to the US FDA, which includes protocols for human clinical studies, with the help of its several regulatory consultants. The Company is in the process of identifying and selecting appropriate partners and collaborators for the intended Phase1/2a human clinical studies for this drug candidate.

About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is in the process of completing an IND application to the US FDA for this drug candidate. The Company cannot project an exact date for filing an IND because of its dependence on a number of external collaborators and consultants, and the effects of recent COVID-19 restrictions.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

ReleaseID: 595724

Cineplex, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Cineplex, Inc. (TSX:CGX) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on June 30, 2020 at 8:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/64554

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 595705

AXS TV And HDNET MOVIES Channels Join SimulTV’s Programming Lineup

SELMA, VA / ACCESSWIRE / June 30, 2020 / AXS TV announced today they have signed a deal to launch AXS TV and its sister channel HDNET MOVIES on SimulTV, an OTT and IPTV platform owned and operated by Virginia-based Interconnect Media Network (IMN) Systems. AXS TV and HDNET MOVIES join SimulTV's eclectic roster of more than 130 channels, providing viewers with music, entertainment and sports programming, and a robust catalog of blockbuster hits-available in both linear and VOD formats.

This summer, AXS TV delivers a star-studded lineup of music-themed programming headlined by the network debut of Ozzy & Jack's World Detour on July 2-chronicling the adventures of father and son duo Ozzy and Jack Osbourne, as they embark across the United States and around the world in search of iconic landmarks and unforgettable activities. And, on July 9, AXS TV presents the all-new artist profile series The Song – Recorded Live @ TGL Farms, where industry influencers Big & Rich, CeeLo Green, Rick Springfield, Travis Tritt, Gretchen Wilson and more discuss the creative process behind their signature hits before taking the stage to perform an intimate set live in front of an audience. SimulTV viewers will also enjoy acclaimed original programs such as the celebrity sit-down series The Big Interview With Dan Rather, all-star jam series Rock & Roll Road Trip With Sammy Hagar, and popular countdown series The Top Ten Revealed; as well as the award-winning series Live From Daryl's House, starring Daryl Hall; and unparalleled combat sports content featuring the premier professional wrestling promotion IMPACT Wrestling.

HDNET MOVIES puts the spotlight on a wide selection of action epics, macabre chillers, legal thrillers, cowboy classics, and more this July-available both streaming and on-demand. SimulTV viewers can expect to enjoy a Wesley Snipes July 4TH four-pack featuring The Marksman, The Contractor, The Art Of War and The Fan; as well as a "48 Hours of Hitchcock" block celebrating The Master Of Suspense with 12 tense favorites including Psycho, Rear Window, The Man Who Knew Too Much and Vertigo; a sinister "Saturday Night Screams" block featuring Friday The 13TH, Night Of The Living and Paranormal Activity; a posse of Old West tales starring John Wayne, Clint Eastwood, Steve McQueen and more in the "High Noon Sundays" block; and a John Grisham trio starring Chris O'Donnell in The Chamber, Tom Cruise in The Firm and Matt Damon in The Rainmaker, among many others.

Viewers can access AXS TV, HDNET MOVIES and other SimulTV content from any phone, tablet or computer via SimulTV's app. Customers can also purchase a set-top box where they can download the SimulTV app from the Google Play store or they can insert their own micro SD card or connect any outside hard drive. The set-top box turns any TV into a Smart TV. Other features included can be found at https://www.simultv.com. Also coming this summer on SimulTV we will be available on Roku, Apple TV, Amazon's Fire Stick and Smart TV's that include: Haier, Sharp, Benq, Philips, Konka, Aoc, Sampo, Boe, Tatung, Teco, Chimei Innolux, Cri, Hua Shu, ICN TV, TV.sohu.com.

"SimulTV provides a unique and innovative way for users to engage with our programming, creating the ultimate social viewing experience," said Randy Brown, Anthem's SVP of Distribution. "We are excited to partner with IMN as we launch two of our most popular properties on SimulTV-giving their audience full access to the diverse array of exclusive original series and box office favorites that have come to define AXS TV and HDNET MOVIES throughout the years. We look forward to supplying them with even more high-quality content as we move into the future."

Steven Turner, SimulTV CEO adds "I grew up listening to AC/DC, and seeing Brian Johnson's A Life on the Road on AXS TV is mind-blowing to me now, and it's great knowing his fans love his show as much as I do."

ABOUT SIMULTV:

SimulTV is an OTT, OTA, and IPTV network founded as a division of Interconnect Media Network Systems by CEO Steven Turner in 2011, currently broadcasting more than 130 live channels worldwide with up to 4k quality. Streaming videos, thousands of movies and Videos On Demand, as well as popular channels including Sony Movie Channel, GetTV, Bloomberg News, InfoWars, HDNet, AXSTV, CineSony, Kid Central, Mythos, The X Zone, Battery Pop, Thrillerz, Euronews, and over a hundred more channels.

SimulTV also offers a Set-Top Box (not required for subscription) which is small enough to fit in a back pocket, enabling viewers to take it with them on the road anywhere in the world. A subscription also provides the ability to connect two additional devices – a mobile phone, tablet, computer, or television. SimulTV apps are free in the Google Play and Apple App Store.

ABOUT AXS TV:

AXS TV is a leading music, entertainment, and lifestyle television network and digital media company controlled by Anthem Sports & Entertainment Inc. The Network is widely available on the major cable, satellite, and telco systems as well as on digital platforms including Sling TV, AT&T TV NOW, and Philo, and via its YouTube, Facebook, and social media channels. In addition to the U.S., AXS TV is also distributed in Canada and the Caribbean. AXS TV's programming broadly appeals to a diverse and impassioned fanbase, offering eclectic content that includes concerts and music performances, celebrity interviews, documentaries, special events, and pop culture series. The Network's signature programs include Dan Rather's "The Big Interview," "Rock & Roll Trip With Sammy Hagar," and "Live From Daryl's House," and concert events such as CMA Fest and Farm Aid. The channel is also the home of IMPACT Wrestling, one of the world's largest entertainment properties. A full list of providers and territories can be found on axs.tv/subscribe. For more information, visit www.axs.tv. Press information is available at axstvmediacenter.com.

ABOUT HDNET MOVIES:

HDNET MOVIES is a television network owned by Anthem Sports & Entertainment, Inc. The channel presents a diverse line-up of over 50 unique films each month, ranging from modern blockbusters to cult classics. HDNET MOVIES is currently available nationally on most major cable, telco and satellite TV providers and is currently in over 12 million homes. For further information, visit www.hdnetmovies.com. Follow HDNET MOVIES on Facebook, Twitter @HDNETMOVIES and YouTube.

###

MEDIA CONTACTS:

JONATHAN REED 
Executive Producer
540.312.5865
Jonathan@SimulTV.com
SimulTV.com

CINDY RONZONI
AXS TV
cronzoni@axs.tv

SEAN GRABIN
AXS TV
sgrabin@axs.tv
 

 

 

 

 

SOURCE: SimulTV

ReleaseID: 595693

Kore.ai Eyes Major Growth in Financial Services

ORLANDO, FL / ACCESSWIRE / June 30, 2020 / Kore.ai, a market-leading Enterprise Conversational AI and Digital UX Platform and Virtual Assistant Solutions company, is pleased to announce the creation of a Financial Services Division dedicated to delivering Banking, Wealth, Insurance and Payments solutions based on its proprietary technology. This business will bring to market a full suite of next-generation customer and employee experiences and assistants, starting with the Kore.ai Virtual Banking Assistant and the Deflect.ai Contact Center solution that are both currently being launched.

"Over the years, we have built strong expertise by serving a multitude of fast-growing clients in the financial services sector. We are continuing this natural momentum by deepening our commitments in this industry to deploy new innovative channels and solutions that enhance the overall customer experience and drive scale and operational efficiency for our clients. We are poised for our next stage of growth, and Financial Services is one of the key areas we focus on for 2020," said Kore.ai Founder and CEO Raj Koneru.

As part of this investment, Kore.ai is excited to announce and welcome our newest team members, Paul Andrusyshyn, who will be leading the division as General Manager and Peter Berbee, who will be driving Product. "We are in the process of rapidly expanding our teams here at Kore.ai. These strategic hires will form a new foundation around our FS business for years to come and we will continue to look for opportunities like this to strengthen our industry leadership position," said Raj.

Kore.ai closed 2019 with over 130% growth. The financial services industry comprises over 40% of the Orlando-based company's total customer base, including 5 of the top 50 international banks. Global 2000 customers across multiple industries (comprising over 30 million users and 500 million annual conversation sessions) use Kore.ai's Conversational AI low-code/no-code platform to deploy Omni-Channel Virtual Assistants for their customers, employees, and businesses.

About Kore.ai

Kore.ai is a market-leading Conversational AI and Digital UX Technology Partner for Global 2000 companies. It provides Conversational AI and Digital UX-rich Virtual Assistants, specifically designed for enterprises, for a diverse range of use cases across industries for engaging customers, employees, and partners. Its end-to-end, comprehensive Virtual Assistant Platform serves as a secure foundation for enterprises to design, build, test, host, and deploy AI-rich virtual assistants across 30+ different Digital and Voice channels. Kore.ai also provides Enterprise Virtual Assistants, pre-trained and pre-built Virtual Assistants for Banking, HR, and IT HelpDesk. Kore.ai partners with top ISVs and global system integrators for helping companies meet their digital transformation needs.

Kore.ai has repeatedly won global analyst acclaim and has been positioned as a Leader in Everest Group's ‘Intelligent Virtual Agents – Technology Vendor Landscape with Products PEAK Matrix® Assessment 2020', Gartner Market Guide 2019 for Conversational Platforms, Gartner Market Guide for Virtual Customer Assistants 2019, and IDC Innovators: Conversational AI Software Platforms 2018, among others. Visit kore.ai to learn more.

Contact:

Karthik G
karthik.gandrajupalli@kore.com

Related Links:
https://kore.ai

SOURCE: Kore.ai Inc.

ReleaseID: 595560

GreenBox POS (OTCQB: GRBX) Releases Next Generation Payment Technology

SAN DIEGO, CA / ACCESSWIRE / June 30, 2020 / GreenBox POS (OTCQB:GRBX) ("GreenBox", "GRBX", the "Company") announced today the completion and launch of the Company's latest technology upgrade.

In development since 2019, the long-awaited technology release features an improved platform, user-friendly interface, and a number of exciting technological improvements that will prove to be a new standard of "best in class." For more info about the next generation of GreenBox, go to http://www.quickcard.me.

The transition of existing clients to the new platform was a seamless success. Future users will be able to enjoy the same uninterrupted experience as GreenBox's new technology allows it to continuously improve performance and capabilities without downtime.

"This is a major capability upgrade for the Company," stated CEO Fredi Nisan. "The development and testing team rose to the challenge, creating a platform that offers an intuitive experience and enhanced features and functions. I feel that with this release, we are set for the next level in the evolution of GreenBox."

About GreenBox POS:

GreenBox POS ("GRBX", "GreenBox") is a groundbreaking technology company that builds customized payment solutions for a variety of industries. GreenBox develops individual disruptive applications integrated in an end-to-end suite of financial products, supporting multitude of industries with an emphasis on Blockchain secured ledger technology. A main business focus is in blockchain ledgering services, capable of handling large commercial processing volumes for its merchant clients in myriad of business verticals. GreenBox is now capable of managing both legacy currency transactions as well as crypto payouts. GreenBox's main operating geography remains the USA, with additional capacity, clientele and technology availability developing in other countries.

For more information, visit the Company's website at https://www.greenboxpos.com/

Forward-Looking Statements Disclaimer:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements.

Public Relations and Media Contact:

GreenBox POS
www.GreenBoxPOS.com
Office: 619-631-4838
Info@GreenBoxPOS.com

SOURCE: GreenBox POS, LLC 

ReleaseID: 595719

Deeper Connect Mini: Decentralized, Private and Secure Internet for the People, launching June 30th on Indiegogo.

NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Deeper Connect Mini, is a small yet powerful device combining cybersecurity, blockchain technology and a sharing economy whose Indiegogo campaign will be launched on June 30th. The device constitutes the accumulated effort of more than two years of active development, and aims at revolutionizing people's relationship with the Internet.

Deeper Connect, has come just at the right moment to propose a solution for cybersecurity worldwide, online privacy and restricted internet access problems introducing a whole new paradigm beyond current VPNs.

Deeper Connect Mini offers a different approach to VPNs, the most notable being its Decentralized Private Network, or in other words, a network constituted by the collection of all devices around the world. In this network each user will be a client and a server at the same time with no central servers.

Given its decentralized architecture, Deeper Connect can easily replace any VPN during travels or at home to access internet content otherwise geographically restricted or for online privacy thanks to the private, open and unrestricted Internet access it provides from anywhere and at any time. But unlike VPNs, users' Internet connection cannot be easily blocked or tracked.

Deeper Connect Mini can establish up to 16 tunnels to other nodes all over the world. By default, they will be established in the US, Europe, Singapore, and China. Nonetheless, users will have the option to define their own smart routes based on the content they want to access.

Also, thanks to optimization of (AtomOS), its lock-free operating system, Deeper Connect is capable of achieving the level and performance of products such as a Palo Alto Network device, which may cost more than $10,000 USD. It is this 7-layer security scanning function that makes Deeper Connect stand on another level with respect to other firewalls for the general public. Deeper Connect can effectively protect IoT devices, by adding a secure gateway between home networks and the external Internet. It will enable a multi-encrypted network firewall function to protect home networks making it extremely difficult for hackers to attack IoT devices on the "cloud server side". It will also recognize and record malicious attacks for further cracking cybercrime. This level of cybersecurity is without a doubt great for remote workers and digital nomads.

Deeper Connect Mini is also useful for those who want to integrate an all in one solution for ads, trackers and malware. Its smart filter function allows users to keep trackers away, avoid being profiled based on their browsing activity, block any threats posed by malware or any intrusive software, push away phishing websites and have a noise free browsing experience with no ads popping up here and there.

In conclusion, Deeper Connect is a revolutionary device combining many different solutions for today's internet privacy and security issues. It has the potential to change the way people interact with the internet, as more and more individuals realize the importance of internet privacy, security and fairness.

The company will be shipping its product worldwide as it aims to create one of the biggest and safest decentralized networks in the world. If you would like to participate in this Indiegogo campaign which starts June 30th, join now:

Indiegogo Pre-Launch Page
https://www.indiegogo.com/projects/deeper-connect-mini–4/coming_soon/x/22964442#/

Indiegogo Launch Page
https://www.indiegogo.com/project/preview/94c3e777#/

Deeper Network Webpage
https://deepernetwork.net/

Contact Info:
Arturo Jiménez
arturo@deeper.network
Phone: +1 (510) 518 6611

SOURCE: Deeper

ReleaseID: 595733

Global Active Pharmaceutical Ingredients (API) Market 2020 Key Players, Segmentation, Consumption, Demand, Growth, Opportunities and Forecast – 2026

WiseGuyRerports.com Presents “Global Active Pharmaceutical Ingredients (API) Market 2020-2026” New Document to its Studies Database

Pune, India – June 30, 2020 /MarketersMedia/

Beginning from the basic detail of the global Active Pharmaceutical Ingredients (API) market, the report consists a thorough analysis of the market profile. The details reveal the fundamental applications and the vital manufacturing techniques which describe the expansion of the Active Pharmaceutical Ingredients (API) market. On the grounds of these details, the market has been segregated into several segments, which also reveals the maximum market share during the review period by 2026. Furthermore, the information about the global Active Pharmaceutical Ingredients (API) market is provided on the basis of key players, competitive players, and the generation of market revenue.

The report includes several national and international players contributing significantly to the global Active Pharmaceutical Ingredients (API) market. The attention is also on the revenue produced from the products, sales of products, and the product categories, which is gaining maximum traction. The report displays the effectiveness of the Active Pharmaceutical Ingredients (API) market with its expansion during the forecast period from 2020 to 2026. The other characteristics of the market have also been evaluated across the wide array of developments, which helps in providing an appropriate insight into the market in the forthcoming period. The analysis of the market has been conducted from the base years, and the assessment tenure continues till 2026.

Get a free Sample report on Active Pharmaceutical Ingredients (API) Market outlook @ https://www.wiseguyreports.com/sample-request/5526807-global-active-pharmaceutical-ingredients-api-market-2020-2026

Key Players

AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.

Drivers & Constraints

The global Active Pharmaceutical Ingredients (API) market report consists of the volume trends, value, and the costing antiquity of the market to produce the maximum growth in the forthcoming period. Moreover, several growth factors, opportunities, and impeding factors have also been evaluated for the advanced study and suggestions pf the market during the forecast period.

Regional Description

The report of the global Active Pharmaceutical Ingredients (API) market provides several strategies on several regions at a global level, where the distinguished players tend to increase profits through partnerships into several areas. The regional report on the global Active Pharmaceutical Ingredients (API) market aims at evaluating the market growth and its potential across the mentioned regions. The report covers the regions such as Latin America, North America, Asia- Pacific, Europe, and the Middle East & Africa with the market predictions. The study of the global Active Pharmaceutical Ingredients (API) market is performed on the basis of these regions to understand the latest trends and the prospects in the given forecast period of 2026.

Make Enquiry on Active Pharmaceutical Ingredients (API) Market Size@ https://www.wiseguyreports.com/enquiry/5526807-global-active-pharmaceutical-ingredients-api-market-2020-2026

Table Of Content:

1 Introduction
2 Market Overview and Qualitative Analysis
3 Segmentation of Global Market by Solution Format
4 Segmentation of Global Market by Advertising Type
5 Segmentation of Global Market by Industry Vertical
6 Segmentation of Global Market by Mobile Device
7 Segmentation of Global Market by Region
8 Competitive Landscape
9 Investing in Global Market: Risk Assessment and Management

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: Wiseguyreports
Address: Office No. 528/524, Amanora Chambers, Magarpatta Road, Hadapsar Pune, Maharashtra 411028
Phone: +162 825 80070 (US) +44 203 500 2763 (UK)
Website: https://www.wiseguyreports.com/

Source URL: https://marketersmedia.com/global-active-pharmaceutical-ingredients-api-market-2020-key-players-segmentation-consumption-demand-growth-opportunities-and-forecast-2026/88966439

Source: MarketersMedia

Release ID: 88966439

Rapid Coagulation Testing Market 2020 Technology, Share, Demand, Opportunity, Projection Analysis Forecast Outlook 2026

A new market study, titled “Discover Rapid Coagulation Testing Market By Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

Pune, India – June 30, 2020 /MarketersMedia/

 

COVID-19 Impact on Global Rapid Coagulation Testing Market – 2020-2026
 

Summary: Rapid Coagulation Testing

Rapid coagulation testing can be defined as the rapid specific testing of bodily blood fluids at the bedside. The rapid coagulation testing are being widely used for management of perioperative coagulation.

The report provides a concentrated opinion of the Rapid Coagulation Testing Market for the reporting during the forecast period, from the years spanning 2020 to 2026. The segments reviewed in the report on the Rapid Coagulation Testing Market shows aspect of progress that is incorporated for improved examination of the worldwide market system. The report also brings to the forefront an unequalled measurement of the market factor evaluation on all quarters scrutinized by the aid of supply chain review and Porter’s five-factor analysis concurrently.  The report, likewise, interprets the factor’s effect that may take sway the expansion of the Rapid Coagulation Testing Market creatively. The report also places a weighty groundwork linked to its level of information with the build-up of all-inclusive country-oriented study to narrate a more superior view of the Rapid Coagulation Testing Market in the imminent period.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Free Sample Report PDF: COVID-19 Impact on Global Rapid Coagulation Testing Market Outlook @

https://www.wiseguyreports.com/sample-request/5404296-covid-19-impact-on-global-rapid-coagulation-testing?utm_medium=Jiten-5.6&utm_source=PR

Understanding the segments helps in identifying the importance of different factors that aid the

Regional Description

The regional markets in Europe, the Middle East, North America, Africa, Asia Pacific, and South America are acknowledged to make a distinction between their effects on the global market in the forecast period. The deduction drawn of the Rapid Coagulation Testing Market is furthermore improved by the examination of the regions included into the global Rapid Coagulation Testing Market.

Drivers and Restraints

The Rapid Coagulation Testing Market factors are attributed to represent the consequences they can have on the development of the Rapid Coagulation Testing Market in the projected period. The veracity of factors and limitations that may exist for market businesses in the Rapid Coagulation Testing Market is intensely calculated to represent the evolving trends that may be documented in the market in the future. The restricting factors of the Rapid Coagulation Testing Market are expected to throw light on the facts that accomplish the standard market progress. The capabilities of the Rapid Coagulation Testing Market is anticipated to allow the companies to create strategies that can be doled out with the issues and thus reduce its control.

Method of Research

The examination of the Rapid Coagulation Testing Market through the forecast period is evaluated based on a collection of reasons that make up Porter’s Five Force Model. The specialists at WGR make use of the SWOT based tools on which the report is adjusted to convey appropriate details about the Rapid Coagulation Testing Market. The wide-ranging research of the market helps the report highlight its in-built limitations, core points, threats, and forecasts.

Key Players

From the point of view of imperative companies, the Rapid Coagulation Testing Market report puts into scrutiny an angle on the market’s existing backdrop along with the innovative trends escalating in the general market. The report on the Rapid Coagulation Testing Market augment the insight of more than a few familiar vendors working in the Rapid Coagulation Testing Market, which consists of an incorporation of imperative as well as the most recent businesses.

View Complete Report / Any Query @

https://www.wiseguyreports.com/enquiry/5404296-covid-19-impact-on-global-rapid-coagulation-testing?utm_medium=Jiten-5.6&utm_source=PR

Key Market Trends | Growth | Share | Sale | Revenue | Manufactures | Technology Component

Players, stakeholders, and other participants in the global Rapid Coagulation Testing market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Rapid Coagulation Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

Table of Content: COVID-19 Impact on Global Rapid Coagulation Testing Market 2026

 

1 Study Coverage

2 Executive Summary 

3 Breakdown Data by Manufacturers 

4 Breakdown Data by Type 

5 Breakdown Data by Application 

11 Company Profiles 

12 Future Forecast 

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 

14 Value Chain and Sales Channels Analysis 

15 Research Findings and Conclusion

16 Appendix 

Continued …

Download Free Sample Copy @

https://www.wiseguyreports.com/sample-request/5404296-covid-19-impact-on-global-rapid-coagulation-testing?utm_medium=Jiten-5.6&utm_source=PR

NOTE : Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

 

About Us:

“Wise Guy Reports Is Part of the Wise Guy Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data for Industries and Governments Around the Globe. Wise Guy Reports Features an Exhaustive List of Market Research Reports from Hundreds of Publishers Worldwide. We Boast a Database Spanning Virtually Every Market Category and an Even More Comprehensive Collection of Market Research Reports Under These Categories and Sub-Categories”.

CONTACT US:

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuyResearch Consultants Pvt Ltd
Phone: +1-646-845-9349
Website: https://www.wiseguyreports.com/

Source URL: https://marketersmedia.com/rapid-coagulation-testing-market-2020-technology-share-demand-opportunity-projection-analysis-forecast-outlook-2026/88966442

Source: MarketersMedia

Release ID: 88966442